Halozyme Therapeutics CEO Helen Torley's 2018 pay rises 12% to $5.8M

Halozyme Therapeutics reports 2018 executive compensation

By ExecPay News

Published: March 22, 2019

Halozyme Therapeutics reported fiscal year 2018 executive compensation information on March 22, 2019.
In 2018, five executives at Halozyme Therapeutics received on average a compensation package of $3M, a 23% increase compared to previous year.
Average pay of disclosed executives at Halozyme Therapeutics
Helen I. Torley, Chief Executive Officer, received $5.8M in total, which increased by 12% compared to 2017. 36% of Torley's compensation, or $2.1M, was in stock awards. Torley also received $832K in non-equity incentive plan, $2.1M in option awards, $725K in salary, as well as $12K in other compensation.
For fiscal year 2018, the median employee pay was $199,899 at Halozyme Therapeutics. Therefore, the ratio of Helen I. Torley's pay to the median employee pay was 29 to one.
Benjamin J. Hickey, Senior Vice President and Chief Commercial Officer, received a compensation package of $3.5M. 43% of the compensation package, or $1.5M, was in stock awards.
Laurie D. Stelzer, Chief Financial Officer, earned $2M in 2018, a 6% increase compared to previous year.
Harry J. Leonhardt, General Counsel, received $1.9M in 2018, which increases by 7% compared to 2017.
Dimitrios Chondros, Chief Medical Officer, earned $1.7M in 2018.

Related executives

Helen Torley

Halozyme Therapeutics

Chief Executive Officer

Laurie Stelzer

Halozyme Therapeutics

Chief Financial Officer

Harry Leonhardt

Halozyme Therapeutics

General Counsel

Dimitrios Chondros

Halozyme Therapeutics

Chief Medical Officer

Benjamin Hickey

Halozyme Therapeutics

Former Senior Vice President, Chief Commercial Officer

You may also like

Source: SEC filing on March 22, 2019.